Fig. 1 | Cellular & Molecular Immunology

Fig. 1

From: The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation

Fig. 1

APG-2575 potentiates the efficacy of an immune checkpoint inhibitor in humanized CD34+ and C57BL/6 mouse models. A, B Tumor outgrowth in different groups, including the control, APG-2575, anti-PD-1 and combination treatment groups, in H1299 tumor-bearing humanized CD34+ model mice and in LLC tumor-bearing C57BL/6 mice. C–F Immunohistochemical analyses of CD8 and GZMB in hu-CD34+ mouse xenograft tumors. G–I Flow cytometric analysis of CD8+, CD8+GZMB+ and CD8+ TNF-α + T cells in hu-CD34+ mouse xenograft tumors. J Tumor outgrowth in Bcl-2 knockdown and overexpression LLC tumor-bearing C57BL/6 mice in the different treatment groups. K–N Differences in BCL-2 expression levels in various cancer types between nonresponders and responders who accepted immunotherapy. KIRC, kidney renal clear cell carcinoma, GC, gastric carcinoma; MEL, melanoma, UC, urothelial carcinoma

Back to article page